ALK‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib by Lianxi Song, Liang Zeng, Yongchang Zhang

Get full text

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer by Lianxi Song, Liang Zeng, Huan Yan, Qinqin Xu, Qing Xia, Jian Lei, Xiaoyan Chen, Xiaoping Hu, Zhan Wang, Hong Liu, Nong Yang, Yongchang Zhang

Get full text

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer by Zhe Huang, Fang Wu, Qinqin Xu, Lianxi Song, Xiangyu Zhang, Zhan Wang, Li Deng, Yongchang Zhang, Liang Zeng, Nong Yang, Xiangxiang Pan, Peifang Wei

Get full text

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study by Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang

Get full text

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study by Lianxi Song, Fei Zhou, Tian Xu, Liang Zeng, Qing Xia, Zhan Wang, Li Deng, Yizhi Li, Haoyue Qin, Huan Yan, Zhe Huang, Jinye Mi, Qinqin Xu, Nong Yang, Caicun Zhou, Yongchang Zhang

Get full text